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Letters to the Editor 
Dear Editor 
The inflammatory basis of asthma is now beyond 
dispute and even mild asthmatics exhibit mast cell 
degranulation, eosinophil infiltration and an increase 
in mononucleur cells in airway mucosal biopsies. The 
chronic nature of this endobronchial inflammation 
may cause damage to ciliated epithelium, which, 
coupled with the laying down of cross-ll&ed collagen 
within the airway wall, leads to partly irreversible 
airway obstruction. Another feature of chronic 
asthma are activated CD4+ T lymphocytes, whose 
numbers seem to correlate with disease severity. As the 
treatment of chronic severe asthma is unsatisfactory in 
many patients clinical trials with cyclosporin A (CsA) 
based on animal model research have now been carried 
out. 
CsA is a T lymphocyte selective immunosuppressive 
agent which has been used extensively to treat patients 
following organ transplantation as part of the 
immunosuppressive regime to counter the rejection 
process. It is only recently (1990) that CsA has been 
considered as an alternative treatment for chronic 
asthma with the advent of Japanese research into 
animal models of bronchial hyperresponsiveness. 
Kukuda et al. demonstrated in guinea pigs with 
bronchial hyperresponsiveness that CsA inhibited 
eosinophil infiltration and bronchial responsiveness 
(1); further investigation showed that delayed phase 
eosinophil infiltration, but not early phase, was 
inhibited correlating with the inhibition of the late 
asthmatic response by CsA in the same model. 
However, there has been conflicting evidence from 
Elnood et al. using rat models, which although demon- 
strating inhibition of the eosinophil and lymphocyte 
bronchial influx by CsA did not show a significant 
decrease in airway hyperresponsiveness (2). 
With the evidence from animal models preliminary 
clinical trials with 12 severe chronic asthmatics 
suggested that CsA might be of benefit in some 
patients with steroid dependent asthma (3). The initial 
results from this trial have now culminated in a double- 
blind, placebo-controlled crossover trial of CsA with 
steroid dependent asthmatics (45). The benefits of 
CsA treatment were found to be: 
decrease in the steroid dose necessary to control the 
asthma. 
better asthma control overall. 
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fewer asthmatic exacerbations requiring an 
increased steroid dose. 
Side effects of the CsA regimes included: 
hypertrichosis. 
parasthesiae. 
tremor and headache. 
mild flu-like symptoms. 
Limited conclusions drawn from this trial supported 
the use of CsA in steroid dependent asthma, and 
recommended further efficacy/safety profiles for CsA 
treatment of milder asthmatic disease. Along with 
FK506 and the new recombinent cytokines CsA may 
yet prove to be a useful alternative treatment for brittle 
or steroid resistent asthma. 
R. SULLIVAN 
15 December 1992 
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Dear Editor 
Evaluation of mean transit time 
In reading the article by Hudson et al. (1) I was 
surprised to find that methodological problems with 
recording mean transit time (MTT) had not been 
adequately addressed or referenced. By using a 
wedge spirometer the volume time trace is distorted 
by the non instantaneous cooling of the gas within 
the spirometer and this distorts the measurement of 
MTT. We have previously shown (2) that this cool- 
ing error can be as large as 15% and can only be 
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avoided by heating the spirometer or using a heated 
pneumotachograph. The problem of truncation of the 
spirogram has previously been argued in the literature 
and limits the usefulness of MTT (3). Other time 
domain indices have been shown to be of value in that 
they more readily identify subjects whose results 
deviate from expected normal values (4). I agree with 
the authors view that MTT is unlikely to play a major 
part in the clinical evaluation of lung function in 
children. However, the reasons behind this finding 
should have been more adequately presented and it is 
possible that other time domain indices, such as a 
truncated first moment, could be extremely useful in a 
paediatric population. 
M. R. MILLER 
4 November 1992 
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Reply to the letter from Dr Miller 
We accept that volume measurements may be over- 
estimated by assuming instantaneous cooling to room 
temperature of air in a wedge spirometer, and that 
mean transit time may therefore be underestimated by 
asmuchas 15%. 
However, because children reach the plateau of the 
forced expirogram much earlier than adults (which is 
why many paediatricians use FEV,.,, rather than FEV 
,.,,, many children having completed the manoeuvre 
within 1 s), the prolonged terminal phase of the 
expirogram, which bedevils studies on adults, is 
seldom seen in children, even in asthmatics, and the 
effects of truncation at 95% FVC would therefore be 
much less than in adults. In our study, readings which 
failed to stabilize were discarded; such tracings usually 
lasted for less than 3 s before the child inspired. As our 
analyses were performed manually, we are not in a 
position to reanalyse the tracings following trunca- 
tion, although we agree that this, and the examination 
of other time domain indices, would be an interesting 
exercise. 
Nevertheless, the effects of delayed cooling cannot 
be ignored and we are grateful to Dr Miller for drawing 
our attention to this problem. 
M. HUDSON, T. K. NINAN AND G. RUSSEL 
3 December 1992 
Dear Editor 
The phenomenon of rifampicin-induced dis- 
colouration of body fluids is well recognized, and urine 
discolouration is widely used as a simple method of 
monitoring treatment compliance. We report a case in 
which the red discolouration disappeared temporarily 
in spite of continued and verified patient compliance. 
A 70-year-old non-insulin-dependent man was 
admitted with smear positive pulmonary tuberculosis. 
Sputum culture subsequently grew Mycotacterium 
tuberculosis, sensitive to the standard drugs. He was 
treated as an in-patient with rifampicin 10 mg kg-’ d-‘, 
isoniazid 300 mg daily, and pyrazinamide 25 mg kg-’ 
d-‘. His only other medication was pyridoxine and 
gliclazide. Initially, as expected, his urine turned 
reddish-orange in colour, but after 3 weeks it was 
noticed that his urine colour had returned to normal, 
even though supervised treatment in hospital had 
continued throughout. 
The N-butanol extraction test was employed in 
further investigation of this phenomenon. Urinary 
rifampicin concentrations of greater than 50 ,ug ml-’ 
are usually visible to the naked eye, but the assay 
detects unmetabolized rifampicin in urine and can con- 
veniently be used to identify urinary concentrations 
down to 2.5 pg ml-’ (1). In this patient the level of 
rifampicin detected in the urine by N-butanol extrac- 
tion was unrecordable. Nevertheless, a sample of his 
urine showed considerable bactericidal activity against 
a precultured StaphyIococcus colony, indicating, in the 
absence of any other active antibiotic, the presence of a 
specific antistaphylococcal agent(s). 
After 2 months treatment, the pyrazinamide was 
discontinued. At this point, the reddish-orange dis- 
colouration of his urine returned. A repeat N-butanol 
extraction assay for rifampicin revealed significant 
amounts of the unchanged drug in the urine. 
It is well known that rifampicin and its metabolites 
are chromogens and impart an orange colouration to 
body secretions, including urine (2). The main 
metabolite, desacetylrifampicin, is microbiologically 
active, with bile as the main route of elimination (3). 
Desacetylation of rifampicin most probably takes 
place in the hepatocyte and results in a more polar 
compound, which facilitates its excretion in bile. 
The ability of rifampicin, pyrazinamide and other 
drugs to induce such reactions reliant on cytochrome 
